Emerging therapeutic targets in multiple sclerosis
Current opinion in neurology, 2006•journals.lww.com
The application of novel and cutting-edge technologies in the fields of genomics and
proteomics is providing a better understanding of the genetic and environmental factors
involved in multiple sclerosis susceptibility and progression, as well as the detection of
biomarkers for disease activity and response to therapy. Implementation of these facilitates
identification of new targets for therapy towards tailoring treatment to the individual patient
with multiple sclerosis.
proteomics is providing a better understanding of the genetic and environmental factors
involved in multiple sclerosis susceptibility and progression, as well as the detection of
biomarkers for disease activity and response to therapy. Implementation of these facilitates
identification of new targets for therapy towards tailoring treatment to the individual patient
with multiple sclerosis.
Summary
The application of novel and cutting-edge technologies in the fields of genomics and proteomics is providing a better understanding of the genetic and environmental factors involved in multiple sclerosis susceptibility and progression, as well as the detection of biomarkers for disease activity and response to therapy. Implementation of these facilitates identification of new targets for therapy towards tailoring treatment to the individual patient with multiple sclerosis.
Lippincott Williams & Wilkins